These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18431358)

  • 1. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?
    Galvão DA; Newton RU; Taaffe DR; Spry N
    Nat Clin Pract Urol; 2008 Jun; 5(6):306-7. PubMed ID: 18431358
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried?
    Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):8. PubMed ID: 20518140
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular risk during androgen deprivation therapy for prostate cancer.
    Jones TH
    BMJ; 2011 May; 342():d3105. PubMed ID: 21610041
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 9. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
    Crawford ED; Moul JW
    Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular effects of androgen depletion and replacement therapy.
    Pinthus JH; Trachtenberg J; Klotz L
    Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164
    [No Abstract]   [Full Text] [Related]  

  • 14. [Androgen deprivation and cardiovascular risk in prostate cancer treatment].
    Leclercq C; Bouchot O; Azzouzi AR; Joly F; Miaadi N; Pfister C; Vincendeau S; de Crevoisier R
    Prog Urol; 2012 Sep; 22 Suppl 2():S48-54. PubMed ID: 23098790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 16. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks.
    Anantharaman A; Friedlander TW
    Oncology (Williston Park); 2015 Jan; 29(1):67-8. PubMed ID: 25592211
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Don't think once, think twice! the cardiovascular effects of androgen deprivation therapy.
    Jefferies ER; Thurairaja R; Persad RA; Rajani R; Phull JS; Bahl A
    BJU Int; 2011 Apr; 107(7):1023-8. PubMed ID: 21438973
    [No Abstract]   [Full Text] [Related]  

  • 19. Feasibility of an intervention for men on androgen deprivation therapy: A research protocol.
    Manson A; Myers J; Billinger S; Ward J; Parker W; Hamilton-Reeves J; Michel C; Maliski SL
    Res Nurs Health; 2019 Oct; 42(5):324-333. PubMed ID: 31389621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on: physical exercise in hemodialysis patients.
    Tentori F
    J Nephrol; 2008; 21(6):808-12. PubMed ID: 19034864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.